Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Nintedanib (Primary) ; Tipiracil/trifluridine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms N-TASK FORCE
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results assessing efficacy and safety, presented at the 42nd European Society for Medical Oncology Congress.
- 11 Oct 2016 Results of phase I part presented at the 41st European Society for Medical Oncology Congress